NTRK重排甲状腺乳头状癌的细胞学特征与不确定诊断
该研究回顾14例NTRK重排PTC的细胞学涂片,发现其核特征轻微(核沟 subtle、核伸长少见、假包涵体罕见),导致TBS III-IV诊断率(64.3%)显著高于NTRK/BRAF野生型(20.0%,P=.013)和BRAFV600E阳性PTC(7.1%,P<.001)。
要点
- NTRK重排PTC常表现为细胞碎片和微滤泡混合结构,乳头状结构少见。
- 核沟常见但多轻微局限,半数病例核圆无伸长,假包涵体仅21.4%。
- NTRK重排PTC的TBS III-IV诊断率显著高于其他分子亚型。
核心结论
- NTRK重排PTC呈现中间型核特征,导致TBS III-IV诊断率显著高于NTRK/BRAF野生型和BRAFV600E阳性PTC。
研究设计与样本
- 回顾性研究,通过FISH或NGS在甲状腺切除标本中检测NTRK重排,复习所有NTRK重排PTC的细胞学涂片,并与25例连续NTRK/BRAF野生型PTC和70例连续BRAFV600E阳性PTC比较术前细胞学诊断。
主要发现
- 14例NTRK重排PTC中,13例(92.9%)有细胞碎片,9例(64.3%)有微滤泡,4例(28.6%)有乳头状结构。
- 核沟常见于11例(78.6%),但多轻微局限;7例(50.0%)核圆无伸长,仅3例(21.4%)见假包涵体。
- TBS III诊断7例(50.0%),TBS IV诊断2例(14.3%),TBS V诊断5例(35.7%)。
- NTRK重排PTC的TBS III-IV诊断率为64.3%,显著高于NTRK/BRAF野生型PTC的20.0%(P=.013)和BRAFV600E阳性PTC的7.1%(P<.001)。
关键数值与推荐
- NTRK重排PTC的TBS III-IV诊断率为64.3%,NTRK/BRAF野生型PTC为20.0%(P=.013),BRAFV600E阳性PTC为7.1%(P<.001)。
临床怎么用
- 细胞学遇到核特征轻微、结构以碎片和微滤泡为主的不确定病例时,应警惕NTRK重排PTC可能。
- 对TBS III-IV诊断的PTC病例,可考虑进行NTRK基因检测以辅助分子分型。
局限性
- 研究样本量较小(仅14例NTRK重排PTC),为回顾性设计。
- 部分文献报道的特征如纤维化碎片在本研究中未一致验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The studies on the cytomorphologic features of NTRK-rearranged papillary thyroid carcinoma (PTC) are limited and some reported characteristics, such as frequent indeterminate diagnoses and presence of fibrotic fragments, are inconsistent in literature. METHODS: NTRK gene rearrangements were detected in thyroidectomy specimens of PTC by either fluorescence in situ hybridization or next-generation sequencing. All the cytologic slides of NTRK-rearranged PTC were reviewed to evaluate the cytomorphologic features. The preoperative cytologic diagnoses of NTRK-rearranged PTC were compared with those of NTRK/BRAF wild-type and BRAFV600E -positive PTC. RESULTS: Fourteen PTC cases were identified to harbor NTRK gene rearrangements. Most of them showed a mixed architectural pattern of cell fragments (n = 13, 92.9%) and microfollicles (n = 9, 64.3%) with relatively rare papillary structures (n = 4, 28.6%). Nuclear grooving was frequently present (n = 11, 78.6%) but was mostly subtle and limited. Seven cases (50.0%) showed rounded nuclei without discernible nuclear elongation, and only 3 (21.4%) cases presented with nuclear pseudoinclusions. Among these cases, 7 (50.0%) were diagnosed as The Bethesda System for Reporting Thyroid Cytopathology (TBS) category III, 2 (14.3%) were diagnosed as TBS IV, and 5 (35.7%) were diagnosed as TBS V. The rate of TBS III-IV diagnoses for NTRK-rearranged PTCs was significantly higher (64.3%) than that for the 25 consecutive NTRK/BRAF wild-type PTCs (20.0%, P = .013) and the 70 consecutive BRAFV600E -positive PTCs (7.1%, P < .001) as selected. CONCLUSIONS: NTRK-rearranged PTC demonstrated intermediate nuclear features, such as subtle nuclear grooving, infrequent nuclear elongation, and rare pseudoinclusions, resulting in a significantly higher rate of TBS III-IV diagnoses compared to PTC with other molecular alterations.
引用
- Lee YC, Hsu CY, Lai CR, et al. NTRK-rearranged papillary thyroid carcinoma demonstrates frequent subtle nuclear features and indeterminate cytologic diagnoses. Cancer Cytopathol. 2021. PMID: 34644010. doi:10.1002/cncy.22522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。